SlideShare a Scribd company logo
Professor Dan Atar, MD, FESC
Dept. of Cardiology
Oslo University Hospital Ullevål
Norway
Vice-President of the ESC (2014-16)
Secretary/Treasurer of the ESC (2018-2020)
2.2.2019 – Mauritius
Rate versus Rhythm Control
in Atrial Fibrillation
CABANA Trial
(Catheter Ablation vs. Anti-arrhythmic Drug Therapy for Atrial Fibrillation)
Aim:
To establish outcomes with either medical therapy or catheter-based
ablation with radiofrequency energy for the management of patients
with new-onset or untreated AF.
Primary endpoint:
All-cause mortality, disabling stroke, serious bleeding, or cardiac arrest.
Dr Douglas Packer
Presented on May 10, 2018 at HRA
International global clinical research trial, 140 centres, 10 countries.
Dr Douglas Packer
Presented on May 10, 2018 at HRA
Dr D. Packer
May 10, 2018
HRA
Dr D. Packer, May 10, 2018, HRA
Eur Heart J. 2018 Aug 7;39(30):2771
CABANA is therefore a negative trial. Does this change our clinical practice to ablate patients with atrial fibrillation? The
answer is no. CABANA enrolled symptomatic patients with atrial fibrillation and showed that catheter ablation is an
effective treatment for these patients. It did not show that there is an indication beyond symptomatic improvement,
because none of the clinical outcome endpoints showed any benefit compared to medical treatment. Most guidelines
recommend catheter ablation as a treatment option after the failure of medical treatment—except for young patients—if
they are treated by very experienced ablationists. CABANA supports this indication in a large number of patients.
CABANA also showed that catheter ablation is rather safe with a relatively low rate of severe complications. Only the 2.2%
pericardial effusion rate gives rise to concern because it may result in cardiac tamponade and, potentially, death. It will be
interesting to see whether the rate of pericardial effusion was lower in patients treated with balloon ablation as compared
to point-by-point radiofrequency ablation.
CABANA is an important trial. It confirms the efficacy of catheter ablation and supports current guidelines that catheter
ablation should be performed in symptomatic patients with atrial fibrillation after at least one drug to treat atrial
fibrillation has been tested
COMMENTARY, EUR HEART J.
23
Thank you for your attention

More Related Content

What's hot

2014 AHA/ACC/HRS Atrial Fibrillation Guideline
2014 AHA/ACC/HRS Atrial Fibrillation Guideline2014 AHA/ACC/HRS Atrial Fibrillation Guideline
2014 AHA/ACC/HRS Atrial Fibrillation Guideline
Sun Yai-Cheng
 
Atrial fibrillation
Atrial  fibrillation Atrial  fibrillation
Atrial fibrillation
Syed Raza
 
Atrial Fibrillation: Rate/ Rhythm control-Non pharmacological management
Atrial Fibrillation: Rate/ Rhythm control-Non pharmacological managementAtrial Fibrillation: Rate/ Rhythm control-Non pharmacological management
Atrial Fibrillation: Rate/ Rhythm control-Non pharmacological managementcardiositeindia
 
nonpharmacological treatment of atrial fibrillation
nonpharmacological treatment of atrial fibrillationnonpharmacological treatment of atrial fibrillation
nonpharmacological treatment of atrial fibrillation
saritadmcardio
 
Persistent Atrial Fibrillation Management: Case preventation
Persistent Atrial Fibrillation Management: Case preventationPersistent Atrial Fibrillation Management: Case preventation
Persistent Atrial Fibrillation Management: Case preventationsalah_atta
 
Mixed results for heart failure therapies, journel club
Mixed results for heart failure therapies, journel clubMixed results for heart failure therapies, journel club
Mixed results for heart failure therapies, journel club
Dr Virbhan Balai
 
Atrial fibrillation...rx
Atrial fibrillation...rxAtrial fibrillation...rx
Atrial fibrillation...rx
Praveen Nagula
 
Guidelines on anticoagulation in Atrial Fibrillation
Guidelines on anticoagulation in Atrial FibrillationGuidelines on anticoagulation in Atrial Fibrillation
Guidelines on anticoagulation in Atrial Fibrillation
Dr Raja Mohammed
 
Atrial fibrillation -latest
Atrial fibrillation -latestAtrial fibrillation -latest
Atrial fibrillation -latest
Praveen Nagula
 
Stieber - Prevention of Postop AF in CT Surgery (2016)
Stieber - Prevention of Postop AF in CT Surgery (2016)Stieber - Prevention of Postop AF in CT Surgery (2016)
Stieber - Prevention of Postop AF in CT Surgery (2016)Jennifer Stieber, MPH, MS
 
2014 AHA/ACC Atrial Fibrillation Guidelines
2014 AHA/ACC Atrial Fibrillation Guidelines2014 AHA/ACC Atrial Fibrillation Guidelines
2014 AHA/ACC Atrial Fibrillation Guidelines
purplevivid
 
ATRIAL FIBRILLATION 2016
ATRIAL FIBRILLATION 2016ATRIAL FIBRILLATION 2016
ATRIAL FIBRILLATION 2016
Ravikanth Moka
 
Management of Heart Failure in ED
Management of Heart Failure in EDManagement of Heart Failure in ED
Management of Heart Failure in ED
Sun Yai-Cheng
 
Rate vs rhythm control, what is new in esc 2020
Rate vs rhythm control, what is new in esc 2020Rate vs rhythm control, what is new in esc 2020
Rate vs rhythm control, what is new in esc 2020
salah_atta
 
Atrial Firbrilation rubayet
Atrial Firbrilation rubayetAtrial Firbrilation rubayet
Atrial Firbrilation rubayet
Nizam Uddin
 
Lec 8 atrial fibrillation for mohs
Lec 8 atrial fibrillation for mohsLec 8 atrial fibrillation for mohs
Lec 8 atrial fibrillation for mohs
EhealthMoHS
 
Current management of atrial fibrillation
Current management of atrial fibrillationCurrent management of atrial fibrillation
Current management of atrial fibrillation
Maame Ama Dodd-Glover
 
Atrial fibrillation
Atrial fibrillationAtrial fibrillation
Atrial fibrillation
Quang Huy Phạm
 
Atrial fibrillation - a surgical perspective
Atrial fibrillation - a surgical perspectiveAtrial fibrillation - a surgical perspective
Atrial fibrillation - a surgical perspective
SrikanthK120
 

What's hot (20)

2014 AHA/ACC/HRS Atrial Fibrillation Guideline
2014 AHA/ACC/HRS Atrial Fibrillation Guideline2014 AHA/ACC/HRS Atrial Fibrillation Guideline
2014 AHA/ACC/HRS Atrial Fibrillation Guideline
 
Atrial fibrillation
Atrial  fibrillation Atrial  fibrillation
Atrial fibrillation
 
Atrial Fibrillation: Rate/ Rhythm control-Non pharmacological management
Atrial Fibrillation: Rate/ Rhythm control-Non pharmacological managementAtrial Fibrillation: Rate/ Rhythm control-Non pharmacological management
Atrial Fibrillation: Rate/ Rhythm control-Non pharmacological management
 
nonpharmacological treatment of atrial fibrillation
nonpharmacological treatment of atrial fibrillationnonpharmacological treatment of atrial fibrillation
nonpharmacological treatment of atrial fibrillation
 
Weaning
WeaningWeaning
Weaning
 
Persistent Atrial Fibrillation Management: Case preventation
Persistent Atrial Fibrillation Management: Case preventationPersistent Atrial Fibrillation Management: Case preventation
Persistent Atrial Fibrillation Management: Case preventation
 
Mixed results for heart failure therapies, journel club
Mixed results for heart failure therapies, journel clubMixed results for heart failure therapies, journel club
Mixed results for heart failure therapies, journel club
 
Atrial fibrillation...rx
Atrial fibrillation...rxAtrial fibrillation...rx
Atrial fibrillation...rx
 
Guidelines on anticoagulation in Atrial Fibrillation
Guidelines on anticoagulation in Atrial FibrillationGuidelines on anticoagulation in Atrial Fibrillation
Guidelines on anticoagulation in Atrial Fibrillation
 
Atrial fibrillation -latest
Atrial fibrillation -latestAtrial fibrillation -latest
Atrial fibrillation -latest
 
Stieber - Prevention of Postop AF in CT Surgery (2016)
Stieber - Prevention of Postop AF in CT Surgery (2016)Stieber - Prevention of Postop AF in CT Surgery (2016)
Stieber - Prevention of Postop AF in CT Surgery (2016)
 
2014 AHA/ACC Atrial Fibrillation Guidelines
2014 AHA/ACC Atrial Fibrillation Guidelines2014 AHA/ACC Atrial Fibrillation Guidelines
2014 AHA/ACC Atrial Fibrillation Guidelines
 
ATRIAL FIBRILLATION 2016
ATRIAL FIBRILLATION 2016ATRIAL FIBRILLATION 2016
ATRIAL FIBRILLATION 2016
 
Management of Heart Failure in ED
Management of Heart Failure in EDManagement of Heart Failure in ED
Management of Heart Failure in ED
 
Rate vs rhythm control, what is new in esc 2020
Rate vs rhythm control, what is new in esc 2020Rate vs rhythm control, what is new in esc 2020
Rate vs rhythm control, what is new in esc 2020
 
Atrial Firbrilation rubayet
Atrial Firbrilation rubayetAtrial Firbrilation rubayet
Atrial Firbrilation rubayet
 
Lec 8 atrial fibrillation for mohs
Lec 8 atrial fibrillation for mohsLec 8 atrial fibrillation for mohs
Lec 8 atrial fibrillation for mohs
 
Current management of atrial fibrillation
Current management of atrial fibrillationCurrent management of atrial fibrillation
Current management of atrial fibrillation
 
Atrial fibrillation
Atrial fibrillationAtrial fibrillation
Atrial fibrillation
 
Atrial fibrillation - a surgical perspective
Atrial fibrillation - a surgical perspectiveAtrial fibrillation - a surgical perspective
Atrial fibrillation - a surgical perspective
 

Similar to 3 dan atar - rate versus rhythm control in af

Highlights from American College of Cardiology 2019
Highlights from American College of Cardiology 2019Highlights from American College of Cardiology 2019
Highlights from American College of Cardiology 2019
ArunSharma10
 
ESC 2010 Research Highlights : A slideshow presentation
ESC 2010 Research Highlights : A slideshow presentationESC 2010 Research Highlights : A slideshow presentation
ESC 2010 Research Highlights : A slideshow presentation
theheart.org
 
HOT CLINICAL TRIALS.pptx
HOT CLINICAL TRIALS.pptxHOT CLINICAL TRIALS.pptx
HOT CLINICAL TRIALS.pptx
ihabmahmoud12
 
AHA 2010 research highlights: A slideshow presentation
AHA 2010 research highlights: A slideshow presentation AHA 2010 research highlights: A slideshow presentation
AHA 2010 research highlights: A slideshow presentation
theheart.org
 
ESC 2012 research highlights: A slideshow presentation
ESC 2012 research highlights: A slideshow presentationESC 2012 research highlights: A slideshow presentation
ESC 2012 research highlights: A slideshow presentation
theheart.org
 
Optimising physiological-endpoints-of-percutaneous-coronary-intervention(1)
Optimising physiological-endpoints-of-percutaneous-coronary-intervention(1)Optimising physiological-endpoints-of-percutaneous-coronary-intervention(1)
Optimising physiological-endpoints-of-percutaneous-coronary-intervention(1)
Ramachandra Barik
 
Updated and Overview of HF Trials in ESC 2020
Updated and Overview of HF Trials in ESC 2020Updated and Overview of HF Trials in ESC 2020
Updated and Overview of HF Trials in ESC 2020
Han Naung Tun
 
Antithrombotic therapy in patients with atrial
Antithrombotic therapy in patients with atrialAntithrombotic therapy in patients with atrial
Antithrombotic therapy in patients with atrial
Swapnil Garde
 
Interventional therapies for hypertension
Interventional therapies for hypertensionInterventional therapies for hypertension
Interventional therapies for hypertension
FAARRAG
 
A fib treatment strategies
A fib treatment strategiesA fib treatment strategies
A fib treatment strategies
faminteractive
 
Value Analysis Committee Presentation (Branded) - PleuraFlow® ACT® System
Value Analysis Committee Presentation (Branded) - PleuraFlow® ACT® SystemValue Analysis Committee Presentation (Branded) - PleuraFlow® ACT® System
Value Analysis Committee Presentation (Branded) - PleuraFlow® ACT® System
Paul Molloy
 
How Early ARNI is Early.pptx
How Early ARNI is Early.pptxHow Early ARNI is Early.pptx
How Early ARNI is Early.pptx
PuneetGupta542512
 
2018 ehra practical guide on the use of non vitamin k antagonist oral anticoa...
2018 ehra practical guide on the use of non vitamin k antagonist oral anticoa...2018 ehra practical guide on the use of non vitamin k antagonist oral anticoa...
2018 ehra practical guide on the use of non vitamin k antagonist oral anticoa...
Vinh Pham Nguyen
 
Coronary flow for the critically ill by Dr Pranesh Jogia
Coronary flow for the critically ill by Dr Pranesh JogiaCoronary flow for the critically ill by Dr Pranesh Jogia
Coronary flow for the critically ill by Dr Pranesh Jogia
CICM 2019 Annual Scientific Meeting
 
Sacubitril Valsartan in Heart failure and Congenital heart disease
Sacubitril Valsartan in Heart failure and Congenital heart diseaseSacubitril Valsartan in Heart failure and Congenital heart disease
Sacubitril Valsartan in Heart failure and Congenital heart disease
pankaj bhosale
 
Unstable coronary patient in the OR
Unstable coronary patient in the ORUnstable coronary patient in the OR
Unstable coronary patient in the OR
Andreas Nygren
 
Dapt after pci how long SEPT 2016
Dapt after pci  how long SEPT 2016Dapt after pci  how long SEPT 2016
Dapt after pci how long SEPT 2016
Rajesh Pandey
 
From vertigo to coma basilar artery occlusion بالاتر از سیاهی رنگی نیست
From vertigo to coma basilar artery occlusion بالاتر از سیاهی رنگی نیستFrom vertigo to coma basilar artery occlusion بالاتر از سیاهی رنگی نیست
From vertigo to coma basilar artery occlusion بالاتر از سیاهی رنگی نیست
ramtinyoung
 
ARNI- Right choice in HF (3).pptx
ARNI- Right choice in HF (3).pptxARNI- Right choice in HF (3).pptx
ARNI- Right choice in HF (3).pptx
Dinakar Thatimatla
 
BETA BLOCKERS AFTER AMI AND NORMAL EJECTION FRACTION.pptx
BETA BLOCKERS AFTER AMI AND NORMAL EJECTION FRACTION.pptxBETA BLOCKERS AFTER AMI AND NORMAL EJECTION FRACTION.pptx
BETA BLOCKERS AFTER AMI AND NORMAL EJECTION FRACTION.pptx
ssuser7307411
 

Similar to 3 dan atar - rate versus rhythm control in af (20)

Highlights from American College of Cardiology 2019
Highlights from American College of Cardiology 2019Highlights from American College of Cardiology 2019
Highlights from American College of Cardiology 2019
 
ESC 2010 Research Highlights : A slideshow presentation
ESC 2010 Research Highlights : A slideshow presentationESC 2010 Research Highlights : A slideshow presentation
ESC 2010 Research Highlights : A slideshow presentation
 
HOT CLINICAL TRIALS.pptx
HOT CLINICAL TRIALS.pptxHOT CLINICAL TRIALS.pptx
HOT CLINICAL TRIALS.pptx
 
AHA 2010 research highlights: A slideshow presentation
AHA 2010 research highlights: A slideshow presentation AHA 2010 research highlights: A slideshow presentation
AHA 2010 research highlights: A slideshow presentation
 
ESC 2012 research highlights: A slideshow presentation
ESC 2012 research highlights: A slideshow presentationESC 2012 research highlights: A slideshow presentation
ESC 2012 research highlights: A slideshow presentation
 
Optimising physiological-endpoints-of-percutaneous-coronary-intervention(1)
Optimising physiological-endpoints-of-percutaneous-coronary-intervention(1)Optimising physiological-endpoints-of-percutaneous-coronary-intervention(1)
Optimising physiological-endpoints-of-percutaneous-coronary-intervention(1)
 
Updated and Overview of HF Trials in ESC 2020
Updated and Overview of HF Trials in ESC 2020Updated and Overview of HF Trials in ESC 2020
Updated and Overview of HF Trials in ESC 2020
 
Antithrombotic therapy in patients with atrial
Antithrombotic therapy in patients with atrialAntithrombotic therapy in patients with atrial
Antithrombotic therapy in patients with atrial
 
Interventional therapies for hypertension
Interventional therapies for hypertensionInterventional therapies for hypertension
Interventional therapies for hypertension
 
A fib treatment strategies
A fib treatment strategiesA fib treatment strategies
A fib treatment strategies
 
Value Analysis Committee Presentation (Branded) - PleuraFlow® ACT® System
Value Analysis Committee Presentation (Branded) - PleuraFlow® ACT® SystemValue Analysis Committee Presentation (Branded) - PleuraFlow® ACT® System
Value Analysis Committee Presentation (Branded) - PleuraFlow® ACT® System
 
How Early ARNI is Early.pptx
How Early ARNI is Early.pptxHow Early ARNI is Early.pptx
How Early ARNI is Early.pptx
 
2018 ehra practical guide on the use of non vitamin k antagonist oral anticoa...
2018 ehra practical guide on the use of non vitamin k antagonist oral anticoa...2018 ehra practical guide on the use of non vitamin k antagonist oral anticoa...
2018 ehra practical guide on the use of non vitamin k antagonist oral anticoa...
 
Coronary flow for the critically ill by Dr Pranesh Jogia
Coronary flow for the critically ill by Dr Pranesh JogiaCoronary flow for the critically ill by Dr Pranesh Jogia
Coronary flow for the critically ill by Dr Pranesh Jogia
 
Sacubitril Valsartan in Heart failure and Congenital heart disease
Sacubitril Valsartan in Heart failure and Congenital heart diseaseSacubitril Valsartan in Heart failure and Congenital heart disease
Sacubitril Valsartan in Heart failure and Congenital heart disease
 
Unstable coronary patient in the OR
Unstable coronary patient in the ORUnstable coronary patient in the OR
Unstable coronary patient in the OR
 
Dapt after pci how long SEPT 2016
Dapt after pci  how long SEPT 2016Dapt after pci  how long SEPT 2016
Dapt after pci how long SEPT 2016
 
From vertigo to coma basilar artery occlusion بالاتر از سیاهی رنگی نیست
From vertigo to coma basilar artery occlusion بالاتر از سیاهی رنگی نیستFrom vertigo to coma basilar artery occlusion بالاتر از سیاهی رنگی نیست
From vertigo to coma basilar artery occlusion بالاتر از سیاهی رنگی نیست
 
ARNI- Right choice in HF (3).pptx
ARNI- Right choice in HF (3).pptxARNI- Right choice in HF (3).pptx
ARNI- Right choice in HF (3).pptx
 
BETA BLOCKERS AFTER AMI AND NORMAL EJECTION FRACTION.pptx
BETA BLOCKERS AFTER AMI AND NORMAL EJECTION FRACTION.pptxBETA BLOCKERS AFTER AMI AND NORMAL EJECTION FRACTION.pptx
BETA BLOCKERS AFTER AMI AND NORMAL EJECTION FRACTION.pptx
 

More from webevo5

Esc guidelines endocarditis by prof deldago
Esc guidelines endocarditis by prof deldagoEsc guidelines endocarditis by prof deldago
Esc guidelines endocarditis by prof deldago
webevo5
 
Mauritius Prof. Bax February 2019
Mauritius Prof. Bax February 2019Mauritius Prof. Bax February 2019
Mauritius Prof. Bax February 2019
webevo5
 
5 dan atar - anticoagulation and stroke prevention in af
5   dan atar - anticoagulation and stroke prevention in af5   dan atar - anticoagulation and stroke prevention in af
5 dan atar - anticoagulation and stroke prevention in af
webevo5
 
4 dan atar - anticoagulation af pci - what do trials say
4   dan atar - anticoagulation af pci - what do trials say4   dan atar - anticoagulation af pci - what do trials say
4 dan atar - anticoagulation af pci - what do trials say
webevo5
 
2 dan atar - esc hf guidelines - clinical aspects
2   dan atar - esc hf guidelines - clinical aspects2   dan atar - esc hf guidelines - clinical aspects
2 dan atar - esc hf guidelines - clinical aspects
webevo5
 
1 dan atar - latest landmark trials in hf-1
1   dan atar - latest landmark trials in hf-11   dan atar - latest landmark trials in hf-1
1 dan atar - latest landmark trials in hf-1
webevo5
 

More from webevo5 (6)

Esc guidelines endocarditis by prof deldago
Esc guidelines endocarditis by prof deldagoEsc guidelines endocarditis by prof deldago
Esc guidelines endocarditis by prof deldago
 
Mauritius Prof. Bax February 2019
Mauritius Prof. Bax February 2019Mauritius Prof. Bax February 2019
Mauritius Prof. Bax February 2019
 
5 dan atar - anticoagulation and stroke prevention in af
5   dan atar - anticoagulation and stroke prevention in af5   dan atar - anticoagulation and stroke prevention in af
5 dan atar - anticoagulation and stroke prevention in af
 
4 dan atar - anticoagulation af pci - what do trials say
4   dan atar - anticoagulation af pci - what do trials say4   dan atar - anticoagulation af pci - what do trials say
4 dan atar - anticoagulation af pci - what do trials say
 
2 dan atar - esc hf guidelines - clinical aspects
2   dan atar - esc hf guidelines - clinical aspects2   dan atar - esc hf guidelines - clinical aspects
2 dan atar - esc hf guidelines - clinical aspects
 
1 dan atar - latest landmark trials in hf-1
1   dan atar - latest landmark trials in hf-11   dan atar - latest landmark trials in hf-1
1 dan atar - latest landmark trials in hf-1
 

Recently uploaded

BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
Rohit chaurpagar
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
DrSathishMS1
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
Catherine Liao
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
VarunMahajani
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
SumeraAhmad5
 

Recently uploaded (20)

BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
 

3 dan atar - rate versus rhythm control in af

  • 1. Professor Dan Atar, MD, FESC Dept. of Cardiology Oslo University Hospital Ullevål Norway Vice-President of the ESC (2014-16) Secretary/Treasurer of the ESC (2018-2020) 2.2.2019 – Mauritius Rate versus Rhythm Control in Atrial Fibrillation
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16. CABANA Trial (Catheter Ablation vs. Anti-arrhythmic Drug Therapy for Atrial Fibrillation) Aim: To establish outcomes with either medical therapy or catheter-based ablation with radiofrequency energy for the management of patients with new-onset or untreated AF. Primary endpoint: All-cause mortality, disabling stroke, serious bleeding, or cardiac arrest. Dr Douglas Packer Presented on May 10, 2018 at HRA International global clinical research trial, 140 centres, 10 countries.
  • 17. Dr Douglas Packer Presented on May 10, 2018 at HRA
  • 18. Dr D. Packer May 10, 2018 HRA
  • 19. Dr D. Packer, May 10, 2018, HRA
  • 20. Eur Heart J. 2018 Aug 7;39(30):2771 CABANA is therefore a negative trial. Does this change our clinical practice to ablate patients with atrial fibrillation? The answer is no. CABANA enrolled symptomatic patients with atrial fibrillation and showed that catheter ablation is an effective treatment for these patients. It did not show that there is an indication beyond symptomatic improvement, because none of the clinical outcome endpoints showed any benefit compared to medical treatment. Most guidelines recommend catheter ablation as a treatment option after the failure of medical treatment—except for young patients—if they are treated by very experienced ablationists. CABANA supports this indication in a large number of patients. CABANA also showed that catheter ablation is rather safe with a relatively low rate of severe complications. Only the 2.2% pericardial effusion rate gives rise to concern because it may result in cardiac tamponade and, potentially, death. It will be interesting to see whether the rate of pericardial effusion was lower in patients treated with balloon ablation as compared to point-by-point radiofrequency ablation. CABANA is an important trial. It confirms the efficacy of catheter ablation and supports current guidelines that catheter ablation should be performed in symptomatic patients with atrial fibrillation after at least one drug to treat atrial fibrillation has been tested COMMENTARY, EUR HEART J.
  • 21.
  • 22.
  • 23. 23 Thank you for your attention